The QualityStocks Daily Tuesday, February 13th, 2024

Today's Top 3 Investment Newsletters

QualityStocks(DBGI) $6.8500 +139.09%

360 Wall Street(OMH) $2.2600 +82.26%

MarketClub Analysis(ARBB) $2.5900 +68.18%

The QualityStocks Daily Stock List

Liberty TripAdvisor (LTRPA)

InvestorPlace, QualityStocks, BUYINS.NET, Trades Of The Day, The Street, StockEarnings, MarketClub Analysis, Zacks, StockMarketWatch, Money Wealth Matters and MarketBeat reported earlier on Liberty TripAdvisor (LTRPA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Liberty TripAdvisor Holdings Inc. (NASDAQ: LTRPA) (FRA: LT0A) is a diversified holding firm that operates as an online travel firm that connects travel partners with travelers.

The firm has its headquarters in Englewood, Colorado and was incorporated in 2014, on August 27th. It has thirty-five companies in its corporate family and serves consumers around the globe, with a focus on the United States and the United Kingdom. The firm operates through its BuySeasons and TripAdvisor subsidiaries.

The company operates through the Experiences and Dining, and the Hotels, Media and Platform segments. The former segment is engaged in the provision of information and services for consumers to experience, book and research activities. On the other hand, the latter segment comprises of technical infrastructure, company-related brand advertising expenses and other costs that support the company’s platform.

The enterprise operates an online restaurant booking platform dubbed TheFork; and a website that provides book, research and experience attractions and activities in travel destinations known as the Viator. Its travel platform offers tools for price comparison, content and online reservation and associated services for restaurants, accommodations and destinations. The enterprise also operates and owns a portfolio of travel media brands and businesses which provide trip-taking and travel-planning resources in the travel industry. This is in addition to offering subscription-based, display-based and click-based advertising services.

The company has a presence in the United Kingdom and the United States as well as other countries. Expanding into new territories, as the firm is currently focused on doing, would not only boost the company’s growth but also bring in more investments into the company.

Liberty TripAdvisor (LTRPA), closed Tuesday's trading session at $1.07, up 33.75%, on 3,007,168 volume. The average volume for the last 3 months is 4.449M and the stock's 52-week low/high is $0.151/$1.68.

Digital Locations, Inc. (DLOC)

MarketClub Analysis and QualityStocks reported earlier on Digital Locations, Inc. (DLOC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Digital Locations, Inc. is a developer of cell tower sites for the 5G revolution. The Company plans to partner or co-develop a portfolio of cell tower sites to help meet the demands of 5G networks. Its aim is to become a “landlord” of tomorrow’s wireless communications assets.

The Company formerly went by the name Carbon Sciences, Inc. It changed its name to Digital Locations, Inc. in September of 2017. Founded in 2006, Digital Locations has its head office in Santa Barbara, California.

Mr. William E. Beifuss, Jr. is President and Chief Executive Officer (CEO) of Digital Locations. Mr. Beifuss is a business executive with considerable real estate development experience. He has been the President, acting Chief Financial Officer (CFO), Secretary, and a Director of the Company since May 2013. Furthermore, he served as Interim CEO of the Company from May 2017 to July 2017 and as CEO of the Company from May 2013 to March 2016.

The expectation is that the 5G wireless networks will be 100 times faster than current 4G LTE networks. Many new 5G broadcast locations are needed because high frequency 5G signals cannot travel farther than 100 meters. The estimation is that more than 1 million new 5G cell towers must be added in the U.S. alone.

5G is the 5th generation mobile network. The prior generations are 1G, 2G, 3G and 4G. 1G delivered analog voice and 2G introduced digital voice. 3G brought mobile data and 4G LTE brought in the era of mobile Internet.

Digital Locations, Inc. (DLOC), closed Tuesday's trading session at $0.0031, up 29.1667%, on 46,945,903 volume. The average volume for the last 3 months is 23,560 and the stock's 52-week low/high is $0.0003/$0.0045.

NetSol Technologies (NTWK)

Wall Street Resources, QualityStocks, Greenbackers, TaglichBrothers, Momentum Traders, InvestorPlace, StockEgg, OTCJournal, 777 Stocks, MarketBeat, StockOodles, SeriousTraders, CoolPennyStocks, HotOTC, The Street, StockMarketWatch, BullRally, Stocktwiter, Hit and Run Candle Sticks, Penny Invest, Zacks, PennyStockVille, PennyTrader Publisher, Access Wallstreet, MadPennyStocks, RedChip, StockRich, StockEarnings, FeedBlitz, The Momentum Traders Network, PennyInvest, MicrocapVoice, Breaking Bulls,, OTCtipReporter, CRWEPicks, Stock Fortune Teller, PennyStockScholar, StreetInsider, StreetAuthority Daily, GorillaTrades, TipRanks, DrStockPick, CRWEWallStreet, PennyOmega, CRWEFinance, StocksEarning, TradersPro, BUYINS.NET, Trading Concepts, Trading Markets, UrPicks, Top Online Stocks, Investing Futures, Penny Stock Rumble, M2 Communications, Mad Stock Pic, Stockhouse, StockHotTips, Stock Rich, MarketClub Analysis, SmallCapVoice, OTC Journal, Red Chip, OTCPicks, OTCReporter, PennyToBuck and StockSpice reported earlier on NetSol Technologies (NTWK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Netsol Technologies Inc. (NASDAQ: NTWK) (FRA: NS9B) is a company focused on designing, developing, marketing and exporting enterprise software solutions to the banking, automobile financing and leasing, and financial services industries globally.

The firm has its headquarters in Calabasas, California and was incorporated in 1995 by Salim Ullah Ghauri. It operates as part of the software-application industry, under the technology sector. The firm serves consumers around the globe.

The enterprise’s offerings include a suite of financial applications for businesses in the finance and leasing industry dubbed NFS Ascent. Its NFS Ascent constituent applications include a web-based application known as Omni Point of Sale; a web-based solution that could be used in conjunction with WFS or any third-party wholesale finance system dubbed the Dealer Auditor Access System; an application for managing and maintaining credit contracts known as the Contract Management System (CMS); and a system for automating and managing the lifecycle of wholesale finance dubbed the Wholesale Finance System. The enterprise also offers a white label platform, which includes Dealer/Admin Tool and Customer Portals dubbed the Otoz Platform; an API-based architecture known as the Otoz Ecosystem; and Otoz Digital Auto-Retail, a white-label SaaS platform. This is in addition to offering system integration, consulting, and information technology products and services. It serves Dow-Jones 30 Industrials, blue chip organizations, vehicle manufacturers, Fortune 500 manufacturers and financial institutions.

The company recently entered into a teaming agreement with Digital Intelligence Systes LLC. This will help grow NetSol’s presence in the U.S. while also opening the company up to new growth and investment opportunities.

NetSol Technologies (NTWK), closed Tuesday's trading session at $2.8162, up 22.4435%, on 279,353 volume. The average volume for the last 3 months is 152,357 and the stock's 52-week low/high is $1.7163/$3.30.

Lion Group Holding (LGHL)

MarketClub Analysis, QualityStocks and StockMarketWatch reported earlier on Lion Group Holding (LGHL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lion Group Holding Ltd. (NASDAQ: LGHL) is a development stage firm which operates as a trading platform.

The firm has its headquarters in Kowloon Bay, Hong Kong and was incorporated in 2020, on February 11th. It serves consumers in Hong Kong and the People’s Republic of China. The firm is party to partnerships with Dawa Technology Co. Ltd. and Grandshores Technology Group Ltd.

The enterprise’s trading platform provides a range of products and services which include securities brokerage services, futures brokerage services, asset management services, insurance brokerage services and CFD trading (contract for difference trading); which can be accessed via applications that are available on the macOS, Windows, Android and iOS systems, to institutional clients and investors. Its trading platform allows its users to trade almost 100 futures products on major futures exchanges worldwide, including the New York Stock Exchange, the Hong Kong Futures Exchange and the Chicago Mercantile Exchange. The enterprise’s platform can also be used to trade derivative products like warrants and callable bear/bull contracts, ETFs, stock indices, futures and commodities on OTC and global exchanges markets. Additionally, it offers TRS services (total return swap services), which comprise of Hong Kong stock basket-linked total return swap services and A-shares.

The company recently entered into a strategic partnership with Dawa Technology to develop the Metaverse AI tool, which will make the construction of the virtual world convenient as well as faster. This partnership will facilitate the company’s entry into the Metaverse field, which may have a positive effect on the company’s growth as well as attracting investments into the firm.

Lion Group Holding (LGHL), closed Tuesday's trading session at $1.16, up 18.3673%, on 556,105 volume. The average volume for the last 3 months is 1.26M and the stock's 52-week low/high is $0.86/$25.18.

Digital Brands Group (DBGI)

QualityStocks, BUYINS.NET, Schaeffer's, The Online Investor and InvestorPlace reported earlier on Digital Brands Group (DBGI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Digital Brands Group Inc. (NASDAQ: DBGI) is engaged in the provision of apparel under different brands on wholesale and direct-to-consumer basis.

The firm has its headquarters in Austin, Texas and was incorporated in 2012. Prior to its name change, the firm was known as Denim L.A. Inc. It operates as part of the retail and whole-discretionary industry, under the consumer discretionary sector, in the retail-discretionary sub-industry and serves consumers in the U.S.

The company operates through the Bailey 44 and DSTLD segments. It brings like-minded direct-to-consumer names under a single portfolio to share data, infrastructure and operational resources in an attempt to reduce redundant fixed costs that are expensive to maintain and difficult to establish. The elimination of administrative responsibilities for their brands allows innovation and creativity to be stimulated and enables brands to be committed to the product and customer experience.

The enterprise provides luxury men’s suiting under the ACE Studios brand and denims under the DSTLD brand. It is also involved in designing, manufacturing and selling women’s apparel, which includes rompers, jackets, sets, bottoms, jumpsuits, tops and dresses, under the Bailey 44 brand. It sells its products directly to the end consumer via its websites, as well as via its own showrooms, select department stores and wholesale channels in specialty stores.

The company recently announced that it would be expanding its e-commerce ecosystem by launching some brands on Amazon. This move adds another customer acquisition channel to the company’s marketing strategy and also increases brand awareness, which may boost the company’s revenues as well as funnel investments into the firm.

Digital Brands Group (DBGI), closed Tuesday's trading session at $6.85, up 139.0925%, on 69,638,174 volume. The average volume for the last 3 months is 153,529 and the stock's 52-week low/high is $2.295/$61.015.

Lundin Mining (LUNMF)

MarketBeat, Zacks, Trades Of The Day, StreetAuthority Daily, Daily Trade Alert, ProfitableTrading, DividendStocks, StreetInsider, TopStockAnalysts, StockOodles, Dividend Opportunities, Wall Street Daily, The Street and Investopedia reported earlier on Lundin Mining (LUNMF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lundin Mining Corp. (OTC: LUNMF) (TSE: LUN) (STO: LUMI) (FRA: GXD) is a diversified base metals mining firm focused on exploring for, developing and mining mineral properties in Chile, Brazil, Sweden, Portugal and the United States.

The firm has its headquarters in Vancouver, Canada and was incorporated in 1994, on September 9th. Prior to its name change in August 2004, the firm was known as South Atlantic Ventures Limited. It operates as part of the copper industry, under the basic materials sector. The firm serves consumers around the globe.

The enterprise primarily produces copper, zinc, nickel, and gold, as well as lead, silver, and other metals. It holds 100% interests in the Chapada mine, an open pit copper-gold mine producing copper concentrate located in Brazil. It also holds 100% interests in the Neves-Corvo mine, a copper and zinc mine producing copper, zinc and lead concentrates located in Portugal; and the Eagle mine, an underground mine located in the United States which produces nickel and copper concentrates. In addition to this, the company holds interests in the Zinkgruvan mine located in Sweden, which produces zinc, lead and copper concentrates. Further, it also holds 80% interests in the Candelaria and Ojos del Salado mining complex located in Chile.

The company, which recently announced production results for the year ended December 2023 and provided production guidance for the period of 2024 through 2026, is focused on increasing production of zinc and copper from its mines and bolstering its overall growth. This is in addition to realizing the expansion of its Neves-Corvo zinc project.

Lundin Mining (LUNMF), closed Tuesday's trading session at $8.04, off by 2.9454%, on 250,971 volume. The average volume for the last 3 months is 1.888M and the stock's 52-week low/high is $5.33/$9.13.

Syra Health (SYRA)

MarketClub Analysis and INO Market Report reported earlier on Syra Health (SYRA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Syra Health Corp. (NASDAQ: SYRA) is a healthcare services firm that is focused on providing health education, virtual health services, managing population health, mental and behavioral health, healthcare training and the provision of healthcare staffing services.

The firm was incorporated in 2020 and has its headquarters in Carmel, Indiana (USA). It operates as part of the healthcare practice management industry, under the healthcare sector. It mainly serves customers in the U.S.

Syra Health leverages its extensive expertise to come up with solutions that support holistic wellness, disease prevention, equity in health and health education. The company earns revenue from two main channels; revenue from healthcare staffing, and revenue from medical communication. The healthcare staffing segment brings in most of the enterprise’s revenue.

The firms is developing Syrenity, which is an on-demand digital platform through which people needing mental health services can get access to those telehealth services. In addition, the company offers a range of health management services that include analytics-as-a-service; digital transformation services; artificial intelligence; enhancing patient engagement; and the development of health apps, among others. The company serves mental health organizations and hospitals, government agencies, managed care facilities, manufacturers of pharmaceuticals, and integrated health networks.

The company remains committed to deepening its reach within its chosen industry verticals in order to better serve its target customers while delivering optimal shareholder value. The firms recently announced the clinching of a healthcare workforce management contract with a county in Virginia, and that it had a secured a federal contract worth $75 million. These developments put the firm on a strong trajectory of reaching more customers and attracting more investments.

Syra Health (SYRA), closed Tuesday's trading session at $2.88, off by 13.5135%, on 1,155,837 volume. The average volume for the last 3 months is 697 and the stock's 52-week low/high is $0.811801/$8.37.

Lelantos Holdings Inc. (LNTO)

QualityStocks and Green Energy Stocks reported earlier on Lelantos Holdings Inc. (LNTO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lelantos Holdings (OTC: LNTO), a company with a focus on sustainable energy, is taking the first step in its acquisition of Eco Management Systems, a full-service commercial and residential solar contractor. According to the announcement, Lelantos executed a memorandum of understanding with Eco to acquire 50% of the company and is now finalizing formal binding agreements. Lelantos reports that acquiring Eco will allow the company to expand its operations as well as add a residential solar program to its offerings. The company is planning on finalizing the acquisition after the successful completion of key milestones that have been identified. Eco is an experienced and highly reputable EPC that has been installing solar for homes and businesses since 2017. Licensed in Arizona, California, Illinois and Texas, Eco has goals that directly align with Lelantos objectives within the industry. Lelantos also announced that Sean Land will be joining the company’s board of directors. A key figure in the residential, commercial and industrial solar space for the past three years, Land has built a 300-plus residential dealer network, and sourced and managed a residential installation network in 42 states. “This acquisition [of Eco] provides us a pivotal component to realize the goal of vertical integration within the renewable energy space,” said Lelantos Holdings COO Joshua Weaver in the press release. “Eco’s reputation as a high-quality and well-respected EPC stands by itself, and I am excited for the value that this relationship brings to Lelantos as a whole.”

To view the full press release, visit

About Lelantos Holdings Inc.

Lelantos Holdings was founded in the spirit of “solution hunting” and features an innovative business structure that is purpose built to acquire or joint venture with established entities in strategic market sectors. With a focus on sustainable energy, Lelantos has a mission of being at the forefront of innovation in a dynamic industry and the goal of operating as a vertically integrated entity to reduce overhead and increase service offerings. Although Lelantos is a new entity, the company’s overall vision has been collectively developed by a seasoned management team over the past decade to culminate its current operations, foster innovation and advance technological developments. For more information about the company, please visit www.Lelantos.Energy.

Lelantos Holdings Inc. (LNTO), closed Tuesday's trading session at $0.4495, even for the day, on 10 volume. The average volume for the last 3 months is 40.879M and the stock's 52-week low/high is $0.105/$2.75.

Optec International Inc. (OPTI)

MarketClub Analysis, OTCtipReporter, QualityStocks, PennyStockProphet, Wall Street Resources, Penny Pick Finders, SmallCapVoice, Profitable Trader Authority, PennyStockScholar, Buzz Stocks, Fierce Analyst, Penny Stock General, Shiznit Stocks, StockOnion, StockWireNews, BeatPennyStocks, Small Cap Firm, MarketBeat, Make Penny Stocks Great Again, HotOTC, StockStreetWire, Epic Stock Picks, Damn Good Penny Picks and Penny Picks reported earlier on Optec International Inc. (OPTI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Optec International (OTC: OPTI) is the focus of a judgment filed by California-based RB Capital Partners Inc., a private investment fund. A recent announcement noted that RB Capital was clarifying the judgment and releasing a shareholder update. According to the announcement, RB Capital observed that it was the largest investor and legitimate shareholder of OPTEC and was “forced to bring a shareholder derivative action against the company to secure our judgment, oust the failing [CEO] Roger Pawson and to try to preserve the assets of the company.” RB Capital filed the lawsuit, noting that Pawson used the company for self-dealing and mismanaged the operations of the corporation at the expense of the shareholders. The judgment was secured in November 2023; the judgment amount was $11.5 million interests and costs, which totaled $14,681,270.50 against Pawson and Optec jointly and severally.

“The court’s judgment also prohibits Pawson from serving as a director and/or CEO of Optec; prohibits Pawson from issuing any class of stock of Optec or transferring any assets of Optec to himself or any third party; prohibits Pawson from using Optec’s assets for his personal gain and to return all ill-gotten funds back to Optec, and finally, the court authorized RB Capital Partners Inc, upon application to the court, to appoint a receiver to control Optec and its assets,” said RB Capital Partners in the press release. “To date we have not sought the appointment of a receiver as we weigh the benefits of doing so, and RB Capital Partners Inc., nor any of its members, are an officer or director of Optec International Inc.”

To view the full press release, visit

About Optec International Inc.

RB Capital Partners is a private investment fund headquartered and incorporated in California. The main investment focus of RB Capital is on small and microcap publicly traded companies trading on the OTC Markets, NASDAQ & New York Stock Exchange. RB Capital predominantly makes debt investments and is known for paying off harmful or convertible debt, giving companies a real chance of success. RB Capital Partners does not manage any outside money nor does it have any investors. It is run and funded solely by Brett Rosen and Deborah Rosen, who each have a 50% ownership stake in the company.

Optec International Inc. (OPTI), closed Tuesday's trading session at $0.0041, off by 8.8889%, on 125,076,653 volume. The average volume for the last 3 months is 1.317M and the stock's 52-week low/high is $0.0002/$0.0047.

atai Life Sciences N.V. (ATAI)

QualityStocks, MarketBeat, The Online Investor, StockMarketWatch, StreetInsider, Dynamic Wealth Report,, MarketClub Analysis, Uncommon Wisdom, Small Caps, PennyToBuck, StockHotTips, CRWEPicks, CRWEFinance, CRWEWallStreet, DrStockPick, PennyOmega, BestOtc, TraderPower, InsiderTrades, Schaeffer's, Broad Street, Awareness Stocks, PsychedelicNewsWire, StockOodles, Street Insider, The Street, TopPennyStockMovers and ProTrader reported earlier on atai Life Sciences N.V. (ATAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In the last couple of years, we have seen interest in psychedelics increase as more studies uncover their hidden benefits. Interest in psilocybin, the psychoactive compound found in hallucinogenic mushrooms, has increased significantly following evidence of its benefits for a range of mental-health conditions, including post-traumatic stress disorder and depression.

However, drug busts of magic mushrooms have also increased, with data from new research showing that the amount of psilocybin seized by authorities has more than tripled in the period between 2017 and 2022. The author of this new research, Joseph Palamar, stated that the study’s findings indicated that the availability of psilocybin mushrooms had been increasing.

The study determined that between 2017 and 2022, the total amount of psilocybin shrooms seized by officers rose to 1,800 pounds from about 500 pounds. Of this total, a majority of the drugs were busted in the West.

Washington University’s Dr. Joshua Siegel, who wasn’t part of this research, stated that the study came at a time when a psychedelic renaissance was happening in the United States. Siegel, whose research focuses on how psychedelics impact the human brain, noted that there was increasing scientific and public interest in the potential therapeutic effects of psychedelics for a range of behavioral and mental health issues.

This comes as more states decriminalize psychedelic substances and allow their use in supervised settings.

The director of the National Institute on Drug Abuse, Dr. Nora Volkow, stated that the study’s results suggested that there was a growing demand for psilocybin. This, she continued, meant that more individuals were using psilocybin, which allowed sellers to sell more of the product.

The research was funded by the National Institute on Drug Abuse. Its results were reported in the “Drug and Alcohol Dependence” journal.

The study’s results align with prior research, including one 2022 study, which found that between 2002 and 2019, the use of psilocybin grew and was primarily driven by individuals aged 26 and above. Additionally, figures from the Substance Abuse and Mental Health Administration suggest that psilocybin is the most popular psychedelic in America. The body’s data showed that in 2022, more than 11% of individuals aged 12 years of age and older revealed that they had used the substance.

At the moment, however, the use of psilocybin for therapeutic use is yet to receive approval from the U.S. Food and Drug Administration. Initial studies have suggested that the use of psychedelics is associated with a risk of psychosis and, in some cases, suicidal ideation.

These seizures by the authorities make it more urgent for psychedelic drug developers such as atai Life Sciences N.V. (NASDAQ: ATAI) to do everything possible so that their pipelines yield approved drugs. In this way, people currently self-medicating with shrooms can have licensed alternatives to address their clinical needs.

atai Life Sciences N.V. (ATAI), closed Tuesday's trading session at $1.74, off by 7.4468%, on 1,026,405 volume. The average volume for the last 3 months is 1.544M and the stock's 52-week low/high is $1.025/$2.39.

Momo Inc. (MOMO)

StocksEarning, MarketClub Analysis, InvestorPlace, Schaeffer's, StockEarnings, Marketbeat, Market Intelligence Center Alert, Zacks, The Street, Trades Of The Day, Kiplinger Today, Daily Trade Alert, StreetInsider, The Street Report,, QualityStocks, The Online Investor, BUYINS.NET, Market Report, Louis Navellier, TradersPro, StreetAuthority Daily, TopStockAnalysts, Wealth Insider Alert, Trading Concepts, TipRanks, StocksImpossible, PennyDoctor, Money Morning, Daily Wealth, FreeRealTime, Greenbackers, StockMarketWatch, Street Insider, Investopedia, First Penny Picks, CrashTrade, Early Bird, DividendStocks, ChartAdvisor, OTCBB Journal, Barchart, Investing Signal, InvestmentHouse, Jason Bond, AskSlapper, Orbit Stocks, Profit Confidential, Promotion Stock Secrets, Short Term Wealth, Terry's Tips, The Best Newsletters, The Stock Dork and One Hot Stock reported earlier on Momo Inc. (MOMO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tens of thousands of frustrated Chinese investors are flocking to social media to vent about the country’s struggling stock market. China’s economy has seen significant volatility in the past few months and is currently experiencing a historic low.

Exasperated people from China are turning to Chinese-language social media accounts to express their frustration and anger with China’s struggling stock market. A post about protecting wild giraffes in Africa by a Chinese language account held by the U.S. embassy in Beijing attracted thousands of stock-market-related comments.

One user asked the U.S. government to help stock investors in China. Many more posts on the matter appeared online before they were apparently removed by censors, likely as part of China’s recent efforts to suppress criticism of the country’s economy.

Over the past three years alone, the Chinese stock market has lost $6 trillion in value amid a prolonged stock market slump. Even though Beijing has attempted to increase confidence in China’s stock market, the Shanghai Composite Index recently experienced a 6.2% fall, its largest weekly decline since October 2018.

The Shenzhen Component Index also fell by 8.1%, dropping by the largest margin in three years. Both the Shanghai Composite Index and the Shenzhen Composite Index lost more than 8% and 15% respectively since the beginning of the year. The blue-chip CAI 300 index, which comprises 300 top stocks listed in both Shenzhen and Shanghai, fell by 4.6% and registered its worst week since October 2022.

China’s economy is now in the midst of a record downturn characterized by extremely poor performance in the real estate sector, historic levels of youth unemployment, deflation and a spiraling birthrate. Furthermore, the International Monetary Fund predicts the nation’s gross domestic product will decrease to 4.6% in 2024 and around 3.5% in 2028 from 5.2% last year. With China ordering the liquidation of embattled and indebted property developer Evergrande in recent weeks, Chinese investors are becoming increasingly worried about the state of their country’s stock market.

The Chinese government and the People’s Bank of China recently announced that they would increase property developers’ access to commercial bank loans as part of efforts to increase confidence in China’s economy. According to Enodo Economics’ chief economist Diana Choyleva, the policies show that developers in a better financial position can expect to receive increased funding while unhealthy developers can expect a similar fate to Evergrande.

The creative way in which Chinese investors leveraged the U.S. embassy’s post on giraffes to vent about the downturn in their investments shows how much power social media providers such as Momo Inc. (NASDAQ: MOMO) can have in enabling people around the world to connect and share views.

Momo Inc. (MOMO), closed Tuesday's trading session at $6.08, off by 3.9494%, on 1,229,074 volume. The average volume for the last 3 months is 451,065 and the stock's 52-week low/high is $5.745/$11.12.

Green Thumb Industries Inc. (GTBIF)

InvestorPlace, QualityStocks, MarketBeat, Wealth Insider Alert, The Online Investor, Daily Trade Alert, Trades Of The Day, TradersPro, The Street, Cabot Wealth, CFN Media Group, StreetInsider, Zacks, Trading For Keeps, wyatt research newsletter, Kiplinger Today, Top Pros' Top Picks, Daily Profit and Technology Profits Daily reported earlier on Green Thumb Industries Inc. (GTBIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent ruling by a federal judge Anne M. Nardacci has dismissed a lawsuit challenging New York’s cannabis licensing program. The lawsuit, filed by two applicants from California, argued that the program unfairly discriminates against non-New York state residents. The ruling would allow the state to grant more licenses, which would have a big effect on a market that is primarily controlled by illegal businesses.

According to Nardacci, the public’s interest in allowing legitimately licensed entities to dominate the market outweighs the issues brought up by the plaintiffs. She noted that the plaintiffs-cited dormant Commerce Provision does not apply to illegal marijuana commerce on federal territory. Rather, due to the lack of Congressional legislation, the provision prohibits states from enacting protectionist policies that hinder interstate commerce.

The legal action, initiated in mid-December by two Los Angeles-based companies, sought a preliminary injunction and temporary restraining orders. Their goal was to halt the state’s licensing procedure during the course of litigation. Nardacci, however, denied the motions, stating that the implementation of regulated permits for the sale of marijuana products would be delayed if an injunction were granted, maintaining the dominance of illegal operators in the market.

New York attorney general Letitia James expressed satisfaction with the court’s decision, noting its significance in ensuring equitable opportunities for disproportionately affected communities within the legal marijuana industry.

New York launched its cannabis program in October last year, intending to give priority to people with past drug convictions who are seeking permits. The strategy aimed to give individuals negatively impacted by the drug war an opportunity before rivals overflowed the market.

Attorneys for the state claimed that more than 1,000 retail locations were expected to be granted licenses this year. They stated that applicants from outside the state are accommodated by the application process, which enables them to prove that they reside in regions that have been disproportionately affected by marijuana prohibition. These measures were anticipated to increase the number of licensed dispensaries, challenging the dominance of black-market vendors who operate unlicensed retail locations.

Critics point to bureaucratic obstacles as the reason for the slow growth of New York’s retail cannabis market, citing delays in the social-equity fund rollout intended to assist applicants in launching stores. The licensing process has also faced legal challenges from excluded individuals and businesses, with a recent lawsuit aiming to further delay the process.

This court victory is a win for the broader cannabis industry, including companies operating in other state markets, such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), since the decision leaves regulators in New York state free to proceed with the rollout of recreational cannabis sales.

Green Thumb Industries Inc. (GTBIF), closed Tuesday's trading session at $12.79, off by 0.466926%, on 374,096 volume. The average volume for the last 3 months is 1.709M and the stock's 52-week low/high is $6.42/$14.30.

The QualityStocks Company Corner

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

WestPark Capital recently published its recap of the recent analyst day event hosted by D-Wave Quantum Inc. (NYSE: QBTS) ("D-Wave"), a leader in the development and delivery of quantum computing systems, software and services. Highlights of the visit included discussions by several customers about the benefits they are experiencing by using D-Wave's solutions, anticipation for the launch of the company's next-generation quantum processor, additional opportunities in government, and a growing number of use cases that have the potential to expand the size of the market opportunity for D-Wave to $100 billion by 2030.

A key excerpt of the report reads, "We came away from the event upbeat on the company, as 1) The move to ‘verticalize' and focus on specific use cases in the near-term in order to create a ‘standard offering' (a page out of the software handbook) is very strategic and will pay dividends for the company, in our view; 2) D-Wave developing its sales team and partner program should lead to an increased customer base, proof of concepts/production deployments, and, ultimately, higher revenue; and 3) We view D-Wave providing positive ROI today for its customers as significant, as this presents opportunities with new enterprises and governments that are looking to incorporate quantum computing into their businesses today."

The report also addressed the progression of 26 proof of concepts, details of customer cost savings using D-Wave technology, product roadmaps for the Advantage2(TM) and Advantage3(TM) systems, details on use cases that could create a $100 billion market opportunity by 2030 for D-Wave, and new go-to-market initiatives.

In the valuation section of the latest report, WestPark Capital reiterated a Buy rating.

To view the full report, visit

To learn more about WestPark Capital's equity research, visit

ROTH MKM attended D-Wave Quantum Inc.'s ("D-Wave" or "QBTS") annual analyst day recently held at the company's research & development headquarters. Suji Desilva, CFA, Managing Director and Senior Research Analyst at ROTH MKM, published an update as part of the investment bank's ongoing equity research coverage to provide investors with a summary of the visit.

Excerpts of the report include the following:

"We believe QBTS leads the industry with 70 commercial customers and has significant pipeline visibility with its 25+ proof-of-concepts underway."

"We were encouraged by multiple QBTS customer presentations that highlight deep and impactful adoption of quantum annealing (QA)."

"We believe these initial applications at lead customers highlight growth opportunity not only for each customer but also in the segments they serve, where additional customer traction can occur."

"In touring QBTS's quantum computing development facilities, we gained greater appreciation of the competitive strength of the company's ~500 global patent base."

Other highlights in the report include discussion of customer presentations that highlighted both significant performance improvements and substantial cost savings, government efforts to include D-Wave's QA technology in budgetary initiatives, impactful adoption of QA technology among multiple sectors, and progress on the company's newer Advantage2TM QA platform, which has reached 1,200 qubits in its latest prototype version.

To view the full report, visit

To learn more about ROTH MKM's equity research, visit

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer


With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service


D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Tuesday's trading session at $1.44, up 6.6667%, on 7,256,504 volume. The average volume for the last 3 months is 961,357 and the stock's 52-week low/high is $0.3962/$3.20.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Neurodegenerative diseases pose a significant challenge in healthcare, yet treatment options remain limited

CNM-Au8(R) has demonstrated remarkable efficacy across various nervous system cell types, with its ability to target fundamental deficiencies associated with dying neurons

Gold nanocrystals found in CNM-Au8 act as miniature mitochondria, providing neurons with much-needed ATP energy while simultaneously converting toxic reactive oxygen species into harmless compounds

Neurodegenerative diseases pose a significant challenge in healthcare, yet treatment options remain limited. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is working on a potentially groundbreaking nanomedicine called CNM-Au8® that aims to revolutionize the approach to addressing nervous system failure associated with these debilitating conditions.

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.


CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Tuesday's trading session at $0.423, up 0.714286%, on 1,929,871 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.20/$.

Recent News


The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ) .

GEMXX expects the growing demand for Ammolite, coupled with the positive outlook for gold prices, to support significant growth over the next 24 months

Last year, GEMXX moved to complement its Ammolite operations with the purchase of gold assets in Canada

The price of gold has held steady above US$2,000 per ounce, coming off a record-breaking 2023 when it rallied to a record-high year-end close

The future looks promising for gold because it is projected to reach new highs in the coming months, according to GEMXX

GEMXX (OTC: GEMZ), a pioneering mine-to-market gold, gemstone and jewelry producer, today announced a stellar start to the year with impressive product deliveries worth $1,051,374 at retail for the month of January. According to the announcement, January's deliveries mark an incredible 600% increase compared to the same period last year, highlighting GEMXX's strong growth trajectory and its effective business strategies. "Our January delivery results are a testament to the hard work and dedication of the GEMXX team," said Jay Maull, CEO of GEMXX Corporation. "Our ability to achieve such significant deliveries is a clear indication of our competitive edge in this industry and our deep understanding of our customers' needs."

To view the full press release, visit

GEMXX Corp. (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources, production facilities, and operational assets, the company maintains control over every aspect of its production process, from gold mining and gemstone extraction to jewelry manufacturing and global distribution.

As a prominent player in the industry, GEMXX stands out as a leading producer of high-quality finished Ammolite jewelry. Notably, it holds the distinction of being the sole public company engaged in Ammolite mining worldwide. In addition to its Ammolite operations, the company is actively involved in gold mining and prides itself on its ability to design and manufacture exquisite jewelry pieces and exceptionally rare, natural fossil decor items for clientele around the globe.

One of GEMXX’s key advantages lies in mining its own gold reserves to be utilized in its jewelry production. This strategic approach provides the company with a cost-saving edge over other producers in the market.

Ammolite is similar to black opal and is a biogenic gem like amber and pearl. It is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses.

GEMXX’s world class gemstone cutters and jewelry designers are continuously leading the Ammolite industry. Its team believes in the company’s philosophy, vision and goals, and works every day to continue to drive the Ammolite industry to the forefront of the gem world.

The company has offices in Las Vegas and Hong Kong.

Projects and Operations

GEMXX has formulated an ambitious growth plan that, while challenging, is deemed attainable. The company’s strategy revolves around bolstering its market share through several key initiatives. Firstly, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.

Secondly, the company plans to venture into untapped markets strategically. By identifying and targeting new areas, GEMXX seeks to establish a presence in regions that present promising opportunities for growth.

Additionally, GEMXX envisions growth through acquisitions. By considering and integrating key services, distribution networks and retail outlets into its fold, the company aims to consolidate its market position and capitalize on synergies for enhanced success.

To cater to the rising demand for its products, GEMXX has placed a primary focus on increasing gemstone production. The company’s southern properties, situated in Alberta, Canada, hold valuable deposits of rough Ammolite gemstone. By tapping into these resources, GEMXX is poised to meet the demand for its exquisite gemstone products and further fuel its expansion plans.


GEMXX possesses significant mineral assets in the form of a Mineral Work Permit covering an 800-acre area and two Ammonite Shell Mineral agreements encompassing 217 acres within the same region. The company’s management effectively operated mines in close proximity to these properties. Moreover, core sampling, along with fossil outcroppings on the riverbanks, confirms a substantial Ammolite resource present in these designated areas.

Both the Mineral Work Permit and the Ammonite Shell Mineral agreements grant GEMXX unrestricted access to all Ammolite resources within their respective demarcations. Notably, the company is not obligated to pay any royalties to third parties, thereby enabling GEMXX to fully capitalize on the potential of these valuable resources.

Furthermore, there are no stringent regulatory conditions that GEMXX must fulfill to gain or retain access to the Ammolite deposits. This freedom of access allows the company to proceed with its mining and production operations unimpeded, providing an advantageous position for future growth and success.

In March 2023, GEMXX made a significant announcement, revealing its acquisition of a 50% ownership stake in Crazy Horse Mining Inc., a Canadian gold mining company with assets situated in the province of British Columbia. As part of this deal, Crazy Horse’s assets, which encompass a 100% interest in two gold projects, called Snow Creek and Rosella Creek, spread across a substantial area exceeding 700 acres, now become part of GEMXX’s portfolio.

Under the terms of this strategic partnership, GEMXX and Crazy Horse will jointly share the expenses related to mining operations on these projects. Additionally, the two companies will share the gold produced from these ventures, leading to a collaborative and mutually beneficial arrangement.

Initial tests conducted on the property, combined with gold already recovered this season, confirm all expectations for the claims and substantiate the company’s estimated extraction target of over 100,000 ounces of easily recoverable gold. To validate and provide a more comprehensive assessment of this estimate, an S-K 1300-compliant Resource Report is scheduled to be conducted during the summer of 2023.

By acquiring this stake in Crazy Horse Mining Inc., GEMXX has positioned itself for further growth in the gold mining sector and is poised to capitalize on cost of goods savings in its jewelry business.

Market Opportunity

Leading independent market research companies such as Data Monitor and GIA estimate the worldwide market for luxury or premium lifestyle products, which include gems and jewelry, at over $90 billion annually and growing. Ammolite sales around the world have seen unprecedented growth over the past 20 years. Worldwide retail sales are now estimated to be over $100 million.

Ammolite jewelry and fossils are featured aboard cruise ships and can be found in specialty shops in almost every cruise port in North America. Asian markets have grown since feng shui master Edward Li called Ammolite the most influential stone of the new millennium, referring to it as the “Seven Color Prosperity Stone.” Home shopping channels in Japan, Australia, France, Germany, the UK, Canada and the U.S. have all featured Ammolite jewelry.

Ammolite and ammonites can also be found on many ecommerce sales platforms, including Amazon, eBay and Etsy. Ammolite is sold around the world in tourist and traditional jewelry markets. The company has established customers in home shopping channels, cruise tourism, jewelry retailers, Asian feng shui markets, Asian retail markets and ecommerce platforms.

Management Team

With over 160 years in Ammolite management, operations, and sales, GEMXX possesses an unparalleled wealth of knowledge and expertise. Its team members have extensive backgrounds in every facet of the Ammolite business, allowing the company to excel in product development, maintain rigorous quality control measures, and maximize profitability. The breadth and depth of the GEMXX team’s experience enable the company to navigate the industry with precision, ensuring that GEMXX remains at the forefront of the Ammolite market. GEMXX leverages its collective wisdom to drive innovation, deliver exceptional products, and optimize business strategies to achieve long-term success.

Jay Maull is Founder, CEO and Chairman of GEMXX. With a career spanning more than three decades, he has been deeply involved in the Ammolite industry, from mining and production to marketing. He has owned and operated the world’s largest Ammolite mine and has delivered exceptional Ammolite products to customers across all continents. He has also established the world’s largest Ammolite ecommerce platform.

Richard Clowater is President of GEMXX. He is a skilled sales and marketing professional with a focus on research, data analysis and strategic planning. He has successfully implemented initiatives to expand markets, boost profits and foster customer loyalty. He has an impressive track record of negotiating sales and contracts worth over $250 million with influential stakeholders, including key purchasing personnel, C-suite executives and government entities at all levels.

Tom Dryden is a Vice President of GEMXX and brings a wealth of experience and expertise to the production and marketing of Ammolite, spanning over 30 years. His extensive involvement in the industry has granted him unparalleled knowledge of the Bearpaw Ammonite bearing formations. As a recognized authority in the field, Mr. Dryden’s research and papers on Canadian Ammonites have garnered global recognition, being published worldwide. In his role at GEMXX, Mr. Dryden assumes the responsibility of overseeing the company’s Canadian-based production facilities. 

P. K. Chung is Business Manager Asia at GEMXX. With a track record of over 25 years in Ammolite business management, production and marketing in Asia, she is a recognized authority in the industry. Based in the Hong Kong gem district, she possesses an intricate understanding of the Asian gem and jewelry markets, including market dynamics, consumer preferences and industry trends specific to the region. Her strategic insights and deep connections enable GEMXX to thrive in this influential market.

GEMXX Corp. (OTC: GEMZ), closed Tuesday's trading session at $0.02304, up 9.7143%, on 13,200 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.02/$0.798.

Recent News

Astrotech Corp. (NASDAQ: ASTC)

The QualityStocks Daily Newsletter would like to spotlight Astrotech Corp. (NASDAQ: ASTC).

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is releasing its financial results for Q2 2024, the period ended Dec. 31, 2023. Highlights of the report include a 512% increase in year-to-date revenue, which reached $1,540,000 compared to $301,000 in the same period in 2023; a strong consolidated balance sheet with $37 million in cash and liquid investments; and a year-to-date FY 2024 gross margin increase of 46% from 38% during the same period in 2023. In addition, the company reported that its 1st Detect subsidiary reentered detection and nondetection testing with the U.S. Transportation Security Administration ("TSA") for cargo security, and its Pro-Control subsidiary, which is focused on applying the Astrotech Mass Spectrometer Technology(TM) in chemical manufacturing process control applications developed by AgLAB, was launched Dec. 12, 2023. The company also reported that production and sales efforts continue for its AgLAB 1000-D2(TM).

"Fiscal year 2024 continued with strong sales at 1st Detect as we successfully fulfilled our two significant Tracer 1000 orders," said Astrotech chair, CEO and chief technology officers Thomas B. Pickens III in the press release. "We are re gaining traction with the checkpoint market, especially with those customers looking to the future, by bringing the world's first ECAC approved mass spectrometer ETD to their airports. Our ruggedized ETD brings the selectivity of a mass spectrometer to the checkpoint, and our customers have reported less false alarms while using our ETD compared to traditional IMS machines. This requires little to no additional training normally associated with using a traditional mass spectrometer. Further, the Pro-Control subsidiary was launched late this quarter, and we look forward to introducing Pro-Control to chemical manufacturers who are using vacuum distillation."

To view the full press release, visit

Astrotech Corp. (NASDAQ: ASTC) is an instrumentation company that designs, manufactures and commercializes solutions. Its solutions include mass spectrometry, process controls, chemical detectors and medical disease detection.

The company was established in 1984 and, prior to 2009, was known as SPACEHAB Inc., a NASA contractor offering technology originally developed for NASA to monitor air quality on the International Space Station. When the Space Shuttle program ended, the company focused on its satellite processing and mass spectrometer instrumentation units and adopted the Astrotech name.

In 2014, Astrotech sold its satellite subsidiary to focus on its Astrotech Technology Inc. (ATi) mass spectrometry solutions, which offer a number of advantages over competing platforms. Notably, Astrotech’s ATi technology is ruggedized, rapid, simple to use and customizable, with hands-free calibration and tuning.

Between 2016 and 2019, the company secured U.S. patents for its technology and achieved European Union (ECAC) certification for the TRACER 1000™, the world’s first mass-spec Explosives Trace Detector (ETD) used in airports worldwide. Astrotech continues to innovate and add to its suite of products, including AgLAB-1000, a process control system, and the BreathTest 1000, a disease detection solution.

Astrotech is headquartered in Austin, Texas.


Astrotech Technologies Inc.

Astrotech Technologies Inc. (ATi) owns and licenses the platform mass spectrometry technology originally developed by 1st Detect. This technology is designed to be less expensive, smaller and easier to use than traditional mass spectrometers.

Unlike other technologies, ATi works under high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The company’s intellectual property includes 18 granted patents, along with extensive trade secrets.

ATi exclusively licenses the Astrotech Mass Spectrometer Technology to the three wholly owned subsidiaries of Astrotech.

1st Detect Corp.

1st Detect Corp. developed the TRACER 1000, the world’s first mass spectrometry-based explosives and narcotics trace detector. 1st Detect ETDs were developed for use at airports, cargo facilities and other secured locations and borders worldwide.

1st Detect’s commercial sales of the TRACER 1000 ETD, consumables and recurring maintenance services brought in $750,000 in total revenue during the fiscal year ended June 30, 2023. The Astrotech subsidiary recently secured two orders for a total of 24 Tracer 1000 units from two Romanian security and telecommunications companies, to be delivered during calendar 2023.

AgLAB Inc.

AgLAB Inc. is developing a series of mass spectrometers for use in the hemp and cannabis market, with an initial focus on optimizing yields in the distillation processes.

AgLAB, which uses the company’s proprietary AgLAB 1000-D2™ mass spectrometer, has been proven to improve distillation oil yields and bottom-line profits for hemp and cannabis producers. During field trials, AgLAB was able to improve ending-weight yields by an average of 24%.

BreathTech Corp.

BreathTech is developing the BreathTest-1000™, a breath analysis tool to screen for volatile organic compound (“VOC”) metabolites found in a person’s breath that could indicate they may have a compromised condition including but not limited to a bacterial or viral infection. The company believes that new tools to aid in the battle against COVID-19 and other diseases remain of the utmost importance to help more quickly identify that an infection may be present.

Market Opportunity

A report by Mordor Intelligence, a research and advisory firm, put the global mass spectrometry market at $6.37 billion in 2023. The market is forecast to grow to $8.63 billion by 2028, achieving a CAGR of 6.25% during the forecast period.

One of the major driving factors for the growth of the mass spectrometry market is technological advancements in mass spectrometer devices, the report states. Key market players are continuously working toward advancing their existing products and launching innovative and advanced mass spectrometer devices.

Another major factor that is expected to boost market growth is increasing research and development expenditure by both government and private entities, according to the report. Mass spectrometry devices are also being used in the detection and analysis of COVID-19 and other disease samples, which may have a positive impact on the market.

Management Team

The Astrotech leadership team includes management executives, as well as industry and technology experts. The company continues to actively expand its talent pool to meet evolving demands.

Thomas B. Pickens III is Chairman, CEO and Chief Technology Officer of Astrotech Corp. He also serves as CEO of Astrotech subsidiaries ATi, 1st Detect, AgLAB Inc. and BreathTech Corp. Previously, he was the founder and president of Beta Computer Systems Inc. and T.B. Pickens & Co. He was founder and general partner of Grace Pickens Acquisition Partners L.P and managing partner of Sumpter Partners. He also served as CEO of Catalyst Energy Corporation and United Thermal Corporation and as president of Golden Bear Corp., United Hydro Inc. and Slate Creek Corp. He received a B.A. in Economics, Computer Science and Engineering from Southern Methodist University.

Jaime Hinojosa, CPA, is CFO at Astrotech Corp. He joined the company in 2015 and has served as its Corporate Controller since 2019. His previous roles with the company include Director of Finance, from 2017 to 2019, and Assistant Controller, from 2015 to 2017. Prior to joining Astrotech, Mr. Hinojosa worked as an Accounting Manager for O’Reilly Auto Parts and gained public accounting experience as an Audit Manager at Burton McCumber & Cortez LLP.

Astrotech Corp. (NASDAQ: ASTC), closed Tuesday's trading session at $8.102, off by 0.46683%, on 7,302 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $7.00/$15.11.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, is reporting financial results for the three months ended Dec. 31, 2023; the company is also reporting a business update. Highlights of the report included the company regaining compliance with the NASDAQ minimum-bid price requirement in January; the achievement of several key milestones, including CARB and federal EPA and NHTSA certification for its Class 1 and Class 3 vehicles, as well as IRS approval as a "qualified manufacturer"; the completion of its lightweight service truck body for the All-Electric Mullen THREE; the submission of a preapplication to the U.S. Department of Energy Advanced Technology Vehicles Manufacturing ("ATVM") loan program to support the company's strategic expansion into domestic battery material processing and manufacturing; and the opening of a battery module and pack development facility in Fullerton, California. "We are coming off our strongest quarter to date for vehicle production and deliveries," said Mullen Automotive CEO and chair David Michery in the press release. "For the three months ended Dec. 31, 2023, the company delivered 231 vehicles. For the 12 months ended Sept. 30, 2023, the company delivered a total of 35 vehicles. Our pivot to focus on commercial EVs last year was a strategic move and has been paying off as we continue to see increased demand across our Campus, Class 1 and Class 3 EVs and PowerUP charging trucks."

To view the full press release, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $6.98, off by 9.3506%, on 928,656 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $6.36/$8993.25.

Recent News

Renovaro BioSciences Inc. (NASDAQ: RENB)

The QualityStocks Daily Newsletter would like to spotlight Renovaro BioSciences Inc. (NASDAQ: RENB) .

Renovaro (NASDAQ: RENB) today announced the completion of its acquisition of GEDi Cube Intl Ltd. ("GEDiCube"). Renovaro, which means renew, combines the power of the AI Health Tech platform of GEDiCube with the advanced cell and gene-therapy Biotech platform of Renovaro Biosciences to accelerate precision, personalized medicine, marking a new era in healthcare innovation. According to the announcement, the two subsidiaries will be under the parent organization, which was renamed Renovaro Inc. "We believe this combination marks a significant milestone in the journey of personalized medicine," said Renovaro's CEO Mark Dybul, MD. "Together, we believe that we are poised to redefine healthcare delivery, making it more precise, effective and accessible."

In addition, GEDiCube announced its entry into a binding letter of intent ("LOI") to acquire 75% of Cyclomics, a Dutch company. Under the LOI terms, the parties have agreed to work in good faith on the drafting of a definitive agreement. "We are very excited about this new opportunity," said Alessio Marcozzi, PhD, co-founder of Cyclomics. "Our Omni-Omic technology was developed to help empower AI platforms and thereby transform non-invasive healthcare solutions to detect cancers and other diseases as early as possible. GEDiCube's innovative deep learning algorithms have created robust multi-omics panels that perform remarkably well. Together, I believe we will change the field."

To view the full press releases, visit and

Renovaro BioSciences Inc. (NASDAQ: RENB), formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) infection.

The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human Phase I/IIa studies that are on track to start by mid-2024. The company’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat, potentially including triple-negative breast cancer, head and neck cancers and mesothelioma.

Renovaro’s proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors. Important confirmatory results from two humanized mouse models using the company’s novel dendritic cell-based therapy, independently conducted by Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy at UCLA, were presented previously at two scientific conferences and were the foundation supporting a pre-IND submission to the U.S. Food and Drug Administration. Notably, Dr. Jewett’s findings from these studies consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response.

Renovaro is headquartered in Los Angeles, California.


Renovaro’s product development strategy is anchored in the use of “non-self” or allogeneic cells that enhance targeted immune response. Its lead candidate, RENB-DC11, is an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors.
Treatment with RENB-DC11 has now been shown to significantly reduce the size of human pancreatic tumors in humanized mice in three independent studies. The reduction in tumor size correlated with statistically significant increases in key components of an immune response.

Pre-IND was completed in June 2023, with IND filing forecast for first half of 2024. First in-human Phase I/IIa trials are predicted shortly after in H1 of 2024, including pancreatic and other solid tumors with poor treatment options and life-expectancy.

Renovaro believes that RENB-DC11 could represent the most promising and effective strategy to achieve life-long remission for a number of common and deadly tumors.

Other Development Candidates

In addition to its lead oncology platform, Renovaro’s development pipeline includes a platform targeting infectious diseases, including:

  • RENB-HV12 – An engineered allogeneic T-Cell vaccine, this therapeutic HIV vaccine candidate enhances immune infiltration, immune killing and immune surveillance. Potential pre-IND submission is planned for first half of 2024, with IND-submission expected in second half of 2024.
  • RENB-HV21 – Leveraging allogeneic NK plus Gamma Delta T (GDT) cells as potential therapy for HIV, ENOB-HV21 shows promising preliminary results without confounding factors. Renovaro owns an exclusive license and has completed the Pre-IND submission, with a potential IND submission and human trials expected in 2024.
  • RENB-HV01 – Caring Cross, a non-profit corporation, has shown that its proprietary CAR-T cells cure HIV in a mouse model. Studies in humans have begun. Renovaro has entered into a profit-sharing sublicense with Caring Cross and would share in profits if the product is commercialized.
  • RENB-HB01 – This therapeutic approach aims to eliminate all HBV rapidly (“seek and kill”) with a two to three dose treatment regimen. It is expected to be applicable for early disease to maximize impact with low risk of toxicity. Pre-IND comments have been received from the FDA for its AAV-delivery system.
    LOI to Merge with GEDi Cube International Ltd.

On August 9, 2023, Renovaro announced its execution of a binding, exclusive letter of intent to merge a subsidiary with cutting-edge health AI company GEDi Cube International Ltd. The combined company is expected to create a potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision in silico drug discovery.

GEDi Cube’s innovative technology, developed over nearly a decade, has already validated earlier diagnoses of lung cancer in humans at a leading university hospital. GEDi Cube has likewise created the early diagnosis technology for 12 additional cancers, including pancreatic and breast cancer.

“I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families,” Dr. Mark Dybul, CEO of Renovaro, stated in the news release.

GEDi Cube is led by CEO Craig Rhodes, who brings to that company tremendous industry experience leading life sciences groups at industry leaders Intel, Oracle and NVIDIA.

Market Opportunity

Pancreatic cancer alone is diagnosed globally in approximately 495,000 people each year, including roughly 64,000 in the U.S. Nearly 466,000 of those patients die annually, including approximately 51,000 in the U.S. Because of limited treatment options, life expectancy is very poor – with an approximately 10% patient survival rate at five years after diagnosis.

The global pancreatic cancer treatment market was valued at $2.15 billion in 2021 and is projected to grow from $2.48 billion in 2022 to $6.85 billion by 2029, according to Fortune Business Insights. That growth represents a CAGR of 15.7% for the forecast period.

A separate report from Fortune Business Insights projects that the global HIV drug market will grow from $30.46 billion in 2021 to $45.58 billion in 2028, recording a CAGR of 5.9% over the forecast period.

According to GlobalData, the value of the market for hepatitis B treatment is forecast to experience a significant increase in the coming years, with revenues expected to grow from $1.6 billion in 2022 to $10.5 billion in 2029. That represents a very rapid CAGR of 30% over the period. An estimated 296 million people suffer from the condition worldwide.

Management Team

Dr. Mark Dybul is the CEO of Renovaro. He has served as a tenured professor in the Department of Medicine at Georgetown University Medical Center since June 2017. He also served as Faculty Co-Director of the Center for Global Health and Quality from 2017-2021. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher and administrator, including as an architect and eventually the Global Ambassador of the U.S. President’s Emergency Plan for AIDS Relief and the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. He is a member of the U.S. National Academy of Medicine.

Luisa Puche is the company’s CFO. She has served as a senior accounting and financial advisor and president of Puche Group LLC from 2015-2019. She served in various key executive roles, including Interim Chief Accounting Officer, at Brightstar Corp., a $10 billion global wireless device services provider. Ms. Puche began her career at Ernst & Young, where she served for approximately 10 years. Leveraging her broad global audit, advisory and corporate expertise, she has provided strong cross-functional leadership experience managing small and large projects for both publicly traded and privately held companies in various industries, including a global implementation of the latest revenue recognition accounting standard for Del Monte, as well as the global implementation of their SOX-404 program.

Francois Binette, Ph.D., is the Chief Operating Officer and Executive Vice President of Research & Development at Renovaro. He has over 25 years of product development expertise in Advanced Therapies and Regenerative Medicine. His broad industry experience spans a wide range of serious medical conditions, from orthopedics to ophthalmology, CNS and immuno-oncology. His career includes positions at Genzyme, Biosyntech, the DePuy Franchise of Johnson and Johnson, Medtronic and Lineage Cell Therapeutics. He received his Ph.D. from Laval University in Québec, followed by post-doctoral training at the Sanford-Burnham Institute in La Jolla and Harvard Medical School in Boston.

Renovaro BioSciences Inc. (NASDAQ: RENB), closed Tuesday's trading session at $1.92, off by 42.8571%, on 948,980 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3928/$5.25.

Recent News

Vision Marine Technologies Inc. (NASDAQ: VMAR)

The QualityStocks Daily Newsletter would like to spotlight Vision Marine Technologies Inc. (NASDAQ: VMAR).

Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator within the performance electric recreational boating industry, announced that Anthony E. Cassella Jr., executive vice president finance and chief accounting officer at MarineMax Inc. (NYSE: HZO) has been appointed to its board of directors; Cassella will serve as an independent director. According to the announcement, the appointment reflects VMAR's leading role in marine technology innovation and underscores its commitment to strong corporate governance; the company noted that the veteran's background and industry knowledge "will bring incredible value to the next chapter of Vision Marine's mission to become the leading provider of electric propulsion for the boating industry." A highly accomplished leader who has played a key role in MarineMax's growth, Cassella oversees key functions at MarineMax, such as finance, mergers and acquisitions, accounting, inventory and treasury. "Anthony brings a wealth of knowledge and experience to the Vision Marine Board, having served in roles of increasing responsibility over his 26-year career with MarineMax," said Vision Marine Technologies CEO Alex Mongeon in the press release. "His progressive leadership at MarineMax aligns with our board's commitment to a thoughtfully executed growth strategy and robust corporate governance. We are thrilled to welcome Anthony to the board and are eager to benefit from his strategic contributions."

To view the full press release, visit

Vision Marine Technologies Inc. (NASDAQ: VMAR) is a global leader and innovator within the performance electric recreational boating industry. The company is engaged in designing and manufacturing electric outboard powertrain systems and related technology. It strives to be a guiding force for change and an ongoing driving factor in fighting the problems associated with waterway pollution by disrupting the traditional boating industry with electric power, in turn directly contributing to zero pollution, zero emission and a noiseless environment.

Vision Marine manufactures hand-crafted, highly durable, low maintenance, environmentally friendly electric recreational powerboats. The company’s business segments include the sale and rental of electric boats, with the majority of its revenue attributable to electric boat sales.

The designs and technology applied to Vision Marine’s boats result in enhanced performance, higher speeds and longer range. Put simply, Vision Marine boats offer a smoother ride than a traditional internal combustion engine motorboat.

The company is headquartered in Montreal.


Vision Marine’s flagship E-Motion™ 180E electric marine powertrain is the first fully electric outboard powertrain combining advanced battery pack, inverter and high efficiency motor with proprietary union assembly between the transmission and motor. Vision Marine’s E-Motion and related technologies in this system utilize extensive control software and are uniquely designed to improve the efficiency of the outboard powertrain. As a result, both range and performance are enhanced.

More than a powerful electric outboard motor, the 180E is a complete powertrain package. The high-tech, marine-specific motor is equipped with multi-sensor captors and independent cooling, providing 180 horsepower.

An onboard charging system allows for quick and easy charging from any shore outlet, whether the vessel is in or out of the water. It implements cutting-edge marine battery packs that are IP67 certified and built to withstand the harshest marine environments. The system is glycol cooled with a controlled heat exchanger, ensuring optimal performance and longevity. A stainless-steel casing protects the battery from corrosion and physical damage over time.

The 180E is built to be integrated with many boat models produced by other marine manufacturers. Since boat manufacturers rarely build their own engines, instead choosing to source them from engine manufacturers, Vision Marine believes the 180E propulsion system can in the future end up powering nearly every recreational boat.

Market Opportunity

According to a report from Future Market Insights, a certified market research organization, the global electric boats market is expected to grow from a value of $5.6 billion in 2023 to $15.1 billion by 2033, achieving a CAGR of 10.4% during the forecast period.

Factors driving growth include rising seaborne commerce activities, a flourishing marine tourism industry and stringent emissions regulations aimed at reducing pollution. In addition, government support for electric speedboat adoption, advances in technological development and research and forecast expansion of needed charging infrastructure are credited as growth drivers.

An emphasis on reducing carbon emissions and encouraging consumer adoption of eco-friendly boats is also likely to drive expansion of the market, the report states.

Management Team

Alexandre Mongeon is Co-Founder and CEO of Vision Marine Technologies. He has served as CEO since 2014. Prior to that, he imported high-performance boats from the United States to Canada for more than 15 years. During much of that time, he also worked as a designer and contractor and managed several new construction projects on the waterfront in and around Montreal. He is a graduate of the School of Construction in Laval, Quebec, with a specialization in electrical systems.

Xavier Montagne is Chief Technical Officer at Vision Marine. Prior to joining the company, he was the CEO of Mac Engineering for six years. While there, he was the electric powerline architect of the Renault Trezor concept car (awarded 2016 Best Concept Car), technical designer of the Zoe E-sport race car driven in Formula-E races from 2016-2019 and senior battery designer for Forsee Power, SAFT, Renault and Peugeot in Europe, to mention a few of the many projects he headed. He received an electronic engineer diploma from IFITEP Paris Polytech in France.

Kulwant Sandher is CFO at Vision Marine. He is a Chartered Professional Accountant with more than 25 years of experience in business and finance. He has served as CFO of multiple public and private companies, including ElectraMeccanica Vehicles Corp., MineSense Technologies Inc., Alba Mineral Ltd., Delta Oil & Gas, Astorius Resources Ltd., Norsemont Mining Inc. and Intigold Mines Ltd. He graduated from Queen Mary College, University of London.

Vision Marine Technologies Inc. (NASDAQ: VMAR), closed Tuesday's trading session at $0.8227, off by 3.0978%, on 16,146 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.69/$5.60.

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology ("I&I") biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as head of business development and sales. Halpert brings extensive pharmaceutical sales and marketing experience and joins Scinai following 14 years at Novartis, most recently having served as marketing and commercial excellence lead for cell and gene therapies for Central, Southern and Eastern Europe. "I am pleased to welcome Liat to Scinai," said Amir Reichman, Scinai's CEO. "Her pharmaceutical sales, marketing and leadership experience, in particular in Israel and Europe, align with our strategic decision to grow Scinai Bioservices CDMO into a trusted provider of drug development services, including for preclinical and clinical trials and GMP manufacturing for clinical supplies."

To view the full press release, visit

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Tuesday's trading session at $0.4832, off by 2.0673%, on 3,190 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.46/$2.51.

Recent News

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Tuesday's trading session at $0.4621, up 5.5023%, on 140,768 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.372/$48.45.

Recent News

Electronic Servitor Publication Network Inc. (OTCQB: XESP)

The QualityStocks Daily Newsletter would like to spotlight Electronic Servitor Publication Network Inc. (OTCQB: XESP).

Electronic Servitor Publication Network Inc. (OTCQB: XESP) is a digital engagement company offering a managed service which provides digital activation and engagement solutions to companies that seek to optimize their growth. Its managed service is powered by a proven, proprietary technology – the Digital Engagement Engine™. This technology provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, which creates digital experiences that accelerate an audience from awareness to action – driving growth.

Electronic Servitor Publication Network’s services are designed to drive growth for both established and developing organizations. Through the optimization of digital interactions within current and new communities, the Digital Engagement Engine™ ensures that client content is relevant, reaches the right audience, and connects with the intended person at the right time.

The company calls it ‘Growth as a Service’.

Client implementation is nearly effortless, since the solution is completely managed by the Electronic Servitor Publication Network team. This business model allows clients to focus on their brands, core product offerings, and content creation, while the company manages the technology and outcome.

The company is headquartered in Minneapolis, Minnesota.


Electronic Servitor Publication Network’s Digital Engagement Engine™ utilizes a combination of automation, unique data management, and a modern workflow built on a microservices architecture to achieve greater reach and lift. Using sophisticated data analysis and smart technology, the Digital Engagement Engine™ provides companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers and revenue streams.

The Digital Engagement Engine™ isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.

Market Outlook

According to a report by, an award-winning market research firm, the global customer engagement solutions market was estimated at $19.3 billion in 2022 and is forecast to grow to $32.2 billion by 2027, achieving a CAGR of 10.8% during the forecast period.

The report notes that these engagement solutions are vital to companies seeking to widen their customer bases, reduce customer churn rates and increase customer retention. These perceived benefits of customer engagement solutions are likely to drive their growing adoption around the globe during the forecast period, according to the report.

Management Team

Peter Hager is President and CEO of Electronic Servitor. He joined the company from Pointward Inc., a medtech customer engagement agency that provided solutions to drive market entry, growth, and commercialization for Fortune 500 health care brands and medtech startups. He has founded and managed multiple technology, professional services and medtech organizations throughout his career. Mr. Hager holds a bachelor’s degree from Macalester College in St. Paul, Minnesota, with concentrations in economics and psychology.

Jim Kellogg is CFO of Electronic Servitor. He has served as the principal of J. Kellogg & Company Inc., a business and tax consultant, since 2005. He has provided legal support to clients’ business valuations, business interruption and divorce property valuations. He has worked as a professional tax adviser since 1983. Mr. Kellogg obtained his JD with emphasis on taxation from Western State University College of Law and was certified as a financial planner by the College for Financial Planning in 1990.

Thomas (Denny) Spruce, RPh, is COO of Electronic Servitor. He oversees company infrastructure, regulatory reporting, and strategic partner relationships, among other roles and responsibilities. He joined the company in March 2022 and, since that time, has implemented foundational support processes, developed contractual relationships with service providers, managed financial and regulatory reporting and overseen contract development and management with the legal team. Mr. Spruce obtained a BS in Pharmacy from the University of Arkansas.

Electronic Servitor Publication Network Inc. (XESP), closed Tuesday's trading session at $0.3553, off by 21.0269%, on 7,124 volume. The average volume for the last 3 months is 3,150 and the stock's 52-week low/high is $0.05/$0.55.

Recent News


The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Tuesday's trading session at $1.55, off by 0.641026%, on 10,949 volume. The average volume for the last 3 months is 12,295 and the stock's 52-week low/high is $1.26/$4.26.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).


Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.


Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Tuesday's trading session at $1.97, off by 2.9557%, on 315,118 volume. The average volume for the last 3 months is 503,826 and the stock's 52-week low/high is $1.89/$37.60.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.